ATA Guidelines Tools

DTC Thyroid Nodules

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/631761

Contents of this Issue

Navigation

Page 1 of 11

Key Points 2 Î Epidemiologic studies have shown the prevalence of palpable thyroid nodules to be approximately 5% in women and 1% in men living in iodine-sufficient parts of the world. By contrast, high-resolution ultrasound (US) can detect thyroid nodules in 19–68% of randomly selected individuals, with higher frequencies in women and the elderly. Î The clinical importance of thyroid nodules rests with the need to exclude thyroid cancer, which occurs in 7–15% depending on age, sex, radiation exposure history, family history, and other factors. Î Thyroid sonography with survey of the cervical lymph nodes (LN) should be performed in all patients with known or suspected thyroid nodules (recommendation 6) Î Thyroid nodules should be assessed for risk of malignancy by the ATA sonographic risk pattern (recommendation 8), not simply by size. Î Not every thyroid nodule >1 cm needs fine-needle aspiration (FNA), and most nodule <1 cm do not need FNA (recommendation 8) Î Thyroid nodule FNA cytology should be reported using diagnostic groups outlined in the Bethesda System for Reporting Thyroid Cytopathology (recommendation 9) Î Molecular testing can be useful in patients with indeterminate FNA cytology, and is primarily considered for patients with AUS/FLUS and FN/SFN cytology (recommendations 13-17) Î Monitoring approaches to patients with benign FNA cytology and those who do not undergo FNA, should be based on the sonographic risk pattern (recommendations 23 and 24) Î Routine TSH suppression is not recommended for patients with benign thyroid nodules (recommendation 25) Î Pregnant women with FNA cytology that is malignant (PTC) can undergo surgery in the second trimester, but surgery can be deferred until after pregnancy if there are no clinically concerning features or substantial growth (recommendation 31) Guideline Grading System Strength of Recommendation Quality of Evidence SR Strong Recommendation H High-quality evidence WR Weak Recommendation M Moderate-quality evidence NR No Recommendation L Low-quality evidence I Insufficient

Articles in this issue

Archives of this issue

view archives of ATA Guidelines Tools - DTC Thyroid Nodules